AUTHORS
Vera M Ripoll, PhD, Shane Whittaker2, Chee Wee Tan3, Tom Gordon4, Jing-Jing Wang, PhD5, Vivien M Chen, MBBS, PhD6
AFFILIATIONS
1 Anzac Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia, Concord Clinical School, University of Sydney, Sydney, New South Wales, Australia
2 Anzac Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia, Concord Clinical School, University of Sydney, Sydney, New South Wales, Australia
3 Department of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
4 College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Bedford Park, Adelaide, South Australia, Australia
5 College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Bedford Park, Adelaide, South Australia, Australia
6 Anzac Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia, Concord Clinical School, University of Sydney, Sydney, New South Wales, Australia, Department of Haematology, Concord Repatriation General Hospital and NSW Health Pathology, Sydney, New South Wales, Australia
ABSTRACT
Background:
Current paradigm of PF4-immune thrombosis (eg. HIT and VITT) attributes platelet (PLT) activation, thrombosis and thrombocytopenia to IgG-PF4 immune complexes via FcγRIIA. Traditionally IgA subclass antibodies are not considered significant in PLT activation/thrombotic disorders and their role in thrombocytopenia remains unclear. We report the first case of anti-PF4 IgA-mediated vaccine-induced thrombosis. We demonstrate direct PLT activation via FcαRI, providing evidence that IgA can directly induce PLT procoagulant responses.
Aim:
To determine whether anti-PF4 IgA defines a novel mechanism of PF4-mediated immune thrombosis that is independent of the canonical IgG/FcγRIIA pathway.
Methods:
Anti-PF4 antibodies were measured by isotype-specific PF4-polyanion ELISA. Anti-PF4 antibodies were affinity-purified from patient serum using PF4-coupled beads and sequenced by mass spectrometry. Recombinant antibodies (rAbs) were reverse-engineered based on the patient-derived amino acid sequences as described (PMID: 37976451), and immunoreactivity was confirmed by ELISA. PLT and neutrophil activation induced by patient plasma and rAbs were assessed by flow cytometry and confocal microscopy. FcαRI-mediated ITAM signalling was interrogated using a FcαRI-blocking antibody (MIP8a), the SYK inhibitor lanraplenib, and compared with inhibition of FcγRIIA using IV.3.
Results:
Patient X: 59-year-old female with extensive mesenteric thrombosis 14 days post ChAdOx1 nCoV‑19 vaccination and markedly elevated D-dimer (25mg/L). IgG-ELISA and serotonin release assay were negative. Despite normal PLT count, flow cytometry diagnostic assay showed heparin-independent plasma induced procoagulant PLT formation. This was not suppressed by FcγRIIA inhibitor (IV.3). Anti-phospholipid antibodies, JAK2 mutations and heritable thrombophilia were not detected. IgA-specific PF4-ELISA was positive.
Mass spectrometry of affinity-purified anti-PF4 antibodies identified a clonotypic IgA1 antibody comprising an IGHV4-59-encoded heavy chain paired with an IGLV1-44-encoded light chain, distinct from the stereotyped IGLV3-21*02 anti-PF4 IgG clonotype characteristic of classical VITT (PMID:35661872). Using rAbs against PF4 alanine mutants, the epitope mapped to the PF4 heparin-binding site. The IgA1 anti-PF4 antibody shared a defining feature of classical VITT antibodies: a highly negatively charged paratope predicted to bind PF4.
Functional assays demonstrated potent PF4-enhanced cellular activation by patient plasma. Compared with plasma containing stereotypical anti-PF4 IgG (IGLV3-21*02 clonotype), patient plasma induced greater procoagulant PLT formation and P-selectin expression even in the absence of PAR1 co-stimulation with TRAP. Patient plasma also promoted activation of neutrophils (CD11b upregulation) that was abrogated by FcαRI blockade. PLT activation was abolished by inhibition of the canonical ITAM signalling effector spleen tyrosine kinase (SYK; lanraplenib). FcγRIIA blockade (IV.3) inhibited activation only in IgG-mediated VITT, whereas FcαRI blockade abrogated activation in Patient X but not in IgG-VITT controls.
Two rAbs were produced: (1) Monomeric IgA (mIgA),(2) anti-PF4 rAb with IgG1 backbone. As predicted, rAb with IgG1 backbone recapitulated stereotypical anti-PF4 IgG FcγRIIA-dependent, FcαRI-independent procoagulant PLT formation. Recombinant mIgA, promoted neutrophil CD11b upregulation and PLT-leukocyte aggregate induction, PLT P-selectin expression and procoagulant PLT formation compared with control IgA -blocked by FcαRI blocking antibody.
Finally, mIgA incubated with PLT rich plasma in presence of exogenous PF4 induced 90% P-selectin and 10% co-expression of annexin-V procoagulant PLT formation indicating a direct PLT effect, independent of neutrophil cross-talk. Recapitulation of the patient phenotype by recombinant mIgA, augmented by PF4 and abolished by FcαRI blockade, provides strong evidence that anti-PF4 IgA1 is a pathogenic antibody driving a novel FcαRI-mediated mechanism of immune thrombosis.
Conclusion:
We describe the first case of anti-PF4 IgA1-mediated vaccine-induced thrombosis and identify a previously unrecognised FcαRI-dependent pathway of PF4-driven immune thrombosis that may underlie cases overlooked by conventional IgG-based diagnostic paradigms. Reassessment of non-thrombocytopenic cohorts for anti-PF4 IgA antibodies may identify an additional population of previously missed patients.
DISCLOSURES
Vivien M Chen, MBBS, PhD: No relevant conflicts of interest to declare.